Suppr超能文献

分析前过程对二氢嘧啶脱氢酶缺陷检测时血浆尿嘧啶定量影响。

Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.

机构信息

Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France.

Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Etienne, France.

出版信息

Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3.

Abstract

AIMS

Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH ) concentrations, as they are essential in reliable DPD-deficiency testing.

METHODS

U and UH concentrations were collected from 14 hospital laboratories. Stability in whole blood and plasma after centrifugation, the type of anticoagulant and long-term plasma storage were evaluated. The variation induced by time and temperature was calculated and compared to an acceptability range of ±20%. Inter-occasion variability (IOV) of U and UH was assessed in 573 patients double sampled for DPD-deficiency testing.

RESULTS

Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains the stability of uracil after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = 0-99%). Notably, 17% of them were assigned with a different phenotype (normal or DPD-deficient) based on the analysis of their two samples. For those having at least one non-compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result.

CONCLUSION

Caution should be taken when interpreting U concentrations if the time before centrifugation exceeds 1 hour at RT, since it rises significantly afterwards. Not respecting the pre-analytical conditions for DPD phenotyping increases the risk of DPD status misclassification.

摘要

目的

在法国,氟嘧啶(FP)给药前必须通过测量患者尿嘧啶(U)血浆浓度来确定二氢嘧啶脱氢酶(DPD)活性。本研究旨在完善 U 和二氢尿嘧啶(UH)浓度的分析前建议,因为它们是可靠的 DPD 缺乏检测所必需的。

方法

从 14 家医院实验室收集 U 和 UH 浓度。评估了离心后全血和血浆中的稳定性、抗凝剂的类型以及长期血浆储存。计算并比较了时间和温度引起的变化与可接受范围±20%。在 573 例 DPD 缺乏检测的患者中,对 U 和 UH 的间变(IOV)进行了双样本评估。

结果

在室温(RT)下离心前储存血液样本不应超过 1 小时,而低温(+4°C)储存可在 5 小时后保持 U 稳定。对于正确双采样的患者,U 的 IOV 达到 22.4%(U 的 SD=17.9%,范围 0-99%)。值得注意的是,根据对其两个样本的分析,其中 17%的患者被分配了不同的表型(正常或 DPD 缺乏)。对于那些至少有一个不合规样本的患者,这一比例上升至 33.8%。采血时间不影响 DPD 表型的结果。

结论

如果在 RT 下离心前超过 1 小时,则应谨慎解释 U 浓度,因为之后 U 浓度会显著升高。不遵守 DPD 表型分析的分析前条件会增加 DPD 状态分类错误的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d3b/10092089/42a9a1d88001/BCP-89-762-g003.jpg

相似文献

1
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3.
7
Can we identify patients carrying targeted deleterious variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.
Clin Chem Lab Med. 2024 Jun 19;62(12):2415-2424. doi: 10.1515/cclm-2024-0317. Print 2024 Nov 26.
8
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
J Pharm Biomed Anal. 2016 Jul 15;126:75-82. doi: 10.1016/j.jpba.2016.04.039. Epub 2016 Apr 29.

引用本文的文献

2
Trifluridine- and tipiracil-induced DPD inhibition mimicking DPD deficiency: a case report.
Front Oncol. 2025 Aug 12;15:1591120. doi: 10.3389/fonc.2025.1591120. eCollection 2025.
3
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.
Cancer Chemother Pharmacol. 2025 Jan 2;95(1):16. doi: 10.1007/s00280-024-04738-5.
5
Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant.
Front Pharmacol. 2024 Sep 23;15:1459565. doi: 10.3389/fphar.2024.1459565. eCollection 2024.
7
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.
Front Oncol. 2023 Jun 20;13:1187052. doi: 10.3389/fonc.2023.1187052. eCollection 2023.
8
Assay performance and stability of uracil and dihydrouracil in clinical practice.
Cancer Chemother Pharmacol. 2023 Mar;91(3):257-266. doi: 10.1007/s00280-023-04518-7. Epub 2023 Mar 11.

本文引用的文献

3
Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma.
Clin Chem Lab Med. 2022 Jan 21;60(5):e112-e115. doi: 10.1515/cclm-2021-0921. Print 2022 Apr 26.
6
Global biochemical analysis of plasma, serum and whole blood collected using various anticoagulant additives.
PLoS One. 2021 Apr 8;16(4):e0249797. doi: 10.1371/journal.pone.0249797. eCollection 2021.
7
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
Ann Oncol. 2021 Jun;32(6):810-811. doi: 10.1016/j.annonc.2021.02.020. Epub 2021 Mar 1.
10
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Clin Transl Sci. 2020 Jul;13(4):761-768. doi: 10.1111/cts.12762. Epub 2020 Apr 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验